These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 34897141)

  • 1. [A case of severe colitis induced by the administration of pembrolizumab for pulmonary adenocarcinoma in a patient with ulcerative colitis].
    Nishimoto N; Sakakibara Y; Ishida H; Ishihara A; Tanaka S; Hasegawa H; Yamamoto S; Nakazuru S; Mori K; Mita E
    Nihon Shokakibyo Gakkai Zasshi; 2021; 118(12):1122-1129. PubMed ID: 34897141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
    Herbst RS; Arkenau HT; Santana-Davila R; Calvo E; Paz-Ares L; Cassier PA; Bendell J; Penel N; Krebs MG; Martin-Liberal J; Isambert N; Soriano A; Wermke M; Cultrera J; Gao L; Widau RC; Mi G; Jin J; Ferry D; Fuchs CS; Petrylak DP; Chau I
    Lancet Oncol; 2019 Aug; 20(8):1109-1123. PubMed ID: 31301962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dramatic, significant metabolic response to a one-time pembrolizumab treatment following a relapse of pre-existing organizing pneumonia in a patient with advanced non-small cell lung cancer: A case report.
    Kato M; Mori M; Miura K; Asao T; Motomura H; Nishino K; Ko R; Koyama R; Hayashi T; Takahashi K
    Thorac Cancer; 2021 Nov; 12(22):3076-3079. PubMed ID: 34617405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Compromise or not? A case report of successful treatment of pembrolizumab-induced hepatitis in a patient with non-small cell lung cancer with low-dose methylprednisolone and bicyclol.
    Liu Y; Zhang J; Yin Z; Zhu X; Xue L; Cao B
    Thorac Cancer; 2020 Jul; 11(7):2023-2030. PubMed ID: 32379397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Case report: reinitiating pembrolizumab treatment after small bowel perforation.
    Beck TN; Kudinov AE; Dulaimi E; Boumber Y
    BMC Cancer; 2019 Apr; 19(1):379. PubMed ID: 31018834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intralymphatic histiocytosis in a patient with lung adenocarcinoma treated with pembrolizumab: a case report.
    Sugano T; Seike M; Funasaka Y; Yoshida M; Takayama R; Okamura K; Nakanishi A; Tanaka T; Takeuchi S; Noro R; Minegishi Y; Kubota K; Saeki H; Gemma A
    J Immunother Cancer; 2019 Feb; 7(1):59. PubMed ID: 30813943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pembrolizumab-induced autoimmune side effects of colon and pancreas in a patient with lung cancer.
    Ofuji K; Hiramatsu K; Nosaka T; Naito T; Takahashi K; Matsuda H; Ohtani M; Imamura Y; Ishizuka T; Nakamoto Y
    Clin J Gastroenterol; 2021 Dec; 14(6):1692-1699. PubMed ID: 34415552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
    Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
    Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Possible Pseudo-progression of Non-small Cell Lung Carcinoma in a Patient With Clinical Hyper-progression Associated With Trousseau Syndrome Who Was Treated With Pembrolizumab: A Case Report.
    Shionoya Y; Hirohashi Y; Takahashi H; Hashimoto M; Nishiyama K; Takakuwa Y; Nakatsugawa M; Kubo T; Kanaseki T; Tsukahara T; Torigoe T
    Anticancer Res; 2021 Jul; 41(7):3699-3706. PubMed ID: 34230169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring antibody binding to T cells in a pembrolizumab-treated patient with lung adenocarcinoma on hemodialysis.
    Osa A; Uenami T; Naito Y; Hirata H; Koyama S; Takimoto T; Shiroyama T; Futami S; Nakatsubo S; Sawa N; Yano Y; Nagatomo I; Takeda Y; Mori M; Kida H; Kumanogoh A
    Thorac Cancer; 2019 Nov; 10(11):2183-2187. PubMed ID: 31520515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pembrolizumab-induced vitiligo in a patient with lung adenocarcinoma: A case report.
    Bulat V; Likic R; Bradic L; Speeckaert R; Azdajic MD
    Br J Clin Pharmacol; 2021 Jun; 87(6):2614-2618. PubMed ID: 33217043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of necitumumab and pembrolizumab combination therapy in patients with Stage IV non-small cell lung cancer.
    Besse B; Garrido P; Cortot AB; Johnson M; Murakami H; Gazzah A; Gil M; Bennouna J
    Lung Cancer; 2020 Apr; 142():63-69. PubMed ID: 32114283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
    Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
    Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-World Efficacy of First-Line Pembrolizumab in Patients With Advanced or Recurrent Non-Small-Cell Lung Cancer and High PD-L1 Tumor Expression.
    Tambo Y; Sone T; Shibata K; Nishi K; Shirasaki H; Yoneda T; Araya T; Kase K; Nishikawa S; Kimura H; Kasahara K
    Clin Lung Cancer; 2020 Sep; 21(5):e366-e379. PubMed ID: 32199806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surgically Resected Second Primary Lung Adenocarcinoma After Pembrolizumab Administration.
    Takamori S; Matsubara T; Haratake N; Miura N; Yamaguchi M; Toyozawa R; Seto T; Taguchi K; Takenoyama M
    Ann Thorac Surg; 2020 Nov; 110(5):e377-e379. PubMed ID: 32339503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disseminated intravascular coagulation in advanced lung adenocarcinoma during first-line pembrolizumab.
    Alberti A; Mancin M; Cortinovis D; Bidoli P; Sala L
    Immunotherapy; 2020 Jun; 12(9):629-633. PubMed ID: 32418466
    [No Abstract]   [Full Text] [Related]  

  • 17. Cholestatic Liver Injury Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma.
    Kurokawa K; Hara M; Iwakami SI; Genda T; Iwakami N; Miyashita Y; Fujioka M; Sasaki S; Takahashi K
    Intern Med; 2019; 58(22):3283-3287. PubMed ID: 31735738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non-small cell lung cancer treated with first-line pembrolizumab.
    Dall'Olio FG; Calabrò D; Conci N; Argalia G; Marchese PV; Fabbri F; Fragomeno B; Ricci D; Fanti S; Ambrosini V; Ardizzoni A
    Eur J Cancer; 2021 Jun; 150():99-107. PubMed ID: 33892411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sarcoid-like reaction of the extrathoracic lymph node in a patient with lung adenocarcinoma treated with pembrolizumab.
    Takamori S; Furubayashi N; Taguchi K; Matsubara T; Fujishita T; Ito K; Yamaguchi M; Toyozawa R; Seto T; Negishi T; Nakamura M; Okamoto T
    Thorac Cancer; 2021 Jul; 12(14):2122-2125. PubMed ID: 34002950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pembrolizumab-induced hypothyroidism caused reversible increased serum creatinine levels: a case report.
    Matsuoka N; Tsuji K; Ichihara E; Hara T; Fukushima K; Toma K; Kitamura S; Inagaki K; Sugiyama H; Wada J
    BMC Nephrol; 2020 Mar; 21(1):113. PubMed ID: 32234009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.